2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-169290
    JAK/HDAC-IN-4
    JAK/HDAC-IN-4 (compound 11 i) is a JAK/HDAC inhibitor with the IC50 values of 0.49 nM and 12 nM for JAK2 and HDAC6, respectively. JAK/HDAC-IN-4 inhibits the cell proliferation and the production of nitric oxide. JAK/HDAC-IN-4 ameliorates psoriasis-like skin lesions in an Imiquimod (HY-B0180)-induced murine model with low toxicity.
    JAK/HDAC-IN-4
  • HY-169300
    KR-40795
    KR-40795 is a potent inhibitor of ATX (autotaxin), with the IC50 of 0.13 μM. KR-40795 plays an important role for liver diseases.
    KR-40795
  • HY-169303
    Gpr35 modulator 2 3049339-96-7
    Gpr35 modulator 2 (compound 52) is a GPR35 modulator. Gpr35 modulator 2 can be used for the study of a various GPR35-related disorders.
    Gpr35 modulator 2
  • HY-169304
    Gpr35 modulator 3 3055887-18-5
    Gpr35 modulator 3 (Example 105) is a Gpr35 modulator with an IC50 < 1 μM. Gpr35 modulator 3 can be used in the study of proliferative, immune, and inflammatory.
    Gpr35 modulator 3
  • HY-169306
    IL-17A inhibitor 4
    IL-17A inhibitor 4 (Example 449) is a potent IL-17A inhibitor. IL-17A inhibitor 4 inhibits HTRF and NHK cells viability with IC50s of 0.028 and 0.0047 μM, respectively.
    IL-17A inhibitor 4
  • HY-169314
    JNK-IN-19 3059122-56-1
    JNK-IN-19 (Compound Q8) is a c-Jun N-terminal kinase inhibitor that is used for treating and/or preventing an injury before, during, or after a surgical procedure.
    JNK-IN-19
  • HY-169317
    DGKζ-IN-6 3058005-75-4
    DGKζ-IN-6 (compound 40) is an oral active DGKζ inhibitor with the IC50 of 45.5 nM. DGKζ-IN-6 inhibits the secretion of IL-2 and can be used for study of cancer and autoimmune diseases.
    DGKζ-IN-6
  • HY-169318
    DGKζ-IN-7 3058006-33-7
    DGKζ-IN-7 (compound 97) is an oral active DGKζ inhibitor with the IC50 of 33.4 nM. DGKζ-IN-6 inhibits the secretion of IL-2 and can be used for study of cancer and autoimmune diseases.
    DGKζ-IN-7
  • HY-169340
    SAR-150640 433212-21-6
    SAR-150640, a selective β3-adrenoceptor agonist, prevents the increase in MMP activity and production observed after LPS stimulation or in cases of chorioamnionitis.
    SAR-150640
  • HY-169370
    STAT3 HiBiT degrader 1 2767166-30-1
    STAT3 HiBiT degrader 1 is a STAT3 HiBiT degrader with a DC50 of less than 0.05 μM in A549 cells.
    STAT3 HiBiT degrader 1
  • HY-169420
    IL-6-IN-1
    IL-6-IN-1 (Compound 22) inhibits the release of IL-6 with an IC50 of 1.065 μM. IL-6-IN-1 exhibits anti-inflammatory efficacy in LPS (HY-D1056)-induced acute lung injury in mouse model.
    IL-6-IN-1
  • HY-169461
    Δ8-THCO 22972-64-1
    Δ8-THCO (delta 8-tetrahydrocannabinol) is a cannabinoid compound that can be isolated from medicinal cannabis (sp. Sativa).
    Δ8-THCO
  • HY-169513
    MK2-IN-7 77607-70-6
    MK2-IN-7 (Compound 144) is a mitogen activated protein kinase-activated protein kinase-2 (MK2) inhibitor. MK2-IN-7 is promising for research of inflammatory diseases, autoimmune diseases and cancer.
    MK2-IN-7
  • HY-169575
    PARP1-IN-36 1606996-12-6
    PARP1-IN-36 (compound 11) is a 4-carboxamido-isoindolinone derivative and a selective PARP-1 inhibitor with a Kd < 0.01 μM. PARP1-IN-36 can be utilized in cancer, cardiovascular diseases, nervous system injury and inflammation research.
    PARP1-IN-36
  • HY-169576
    LRRK2-IN-16 852375-30-5
    LRRK2-IN-16 (compound 25) is a LRRK2 kinase inhibitor with an IC50 < 5 μM. LRRK2-IN-16 can be utilized in neurodegenerative disorders and autoimmune disorders research.
    LRRK2-IN-16
  • HY-16958R
    PD 404182 (Standard) 72596-74-8
    Paris saponin VII (Standard) is the analytical standard of Paris saponin VII. This product is intended for research and analytical applications. Paris saponin VII (Chonglou Saponin VII) is a steroidal saponin isolated from the roots and rhizomes of Trillium tschonoskii. Paris saponin VII-induced apoptosis in K562/ADR cells is associated with Akt/MAPK and the inhibition of P-gp. Paris saponin VII attenuates mitochondrial membrane potential, increases the expression of apoptosis-related proteins, such as Bax and cytochrome c, and decreases the protein expression levels of Bcl-2, caspase-9, caspase-3, PARP-1, and p-Akt. Paris saponin VII induces a robust autophagy in K562/ADR cells and provides a biochemical basis in the treatment of leukemia.
    PD 404182 (Standard)
  • HY-169609
    JNK-IN-22 771503-50-5
    JNK-IN-22 (Compound 58) is a JNK-1 inhibitor.
    JNK-IN-22
  • HY-169630
    DBMB 314027-66-2
    DBMB is an inhibitor of spleen tyrosine kinase (Syk), capable of significantly inhibiting the activity of Syk kinase. DBMB exhibits anti-inflammatory activity by suppressing the signaling of NF-κB, which in turn reduces the production of inflammatory mediators such as nitric oxide (NO) and prostaglandin E2 (PGE2). DBMB can be utilized in research on inflammatory diseases.
    DBMB
  • HY-169703
    SPA0355 1251839-15-2
    SPA0355 is a thiourea derivative that has antioxidant and anti-inflammatory properties. SPA0355 inhibits the RANKL (receptor activator of nuclear factor κB ligand) induced osteoclast formation in primary bone marrow-derived macrophages. SPA0355 also suppresses the activation of the MAPKs, Akt, and NF-κB pathways. Additionally, SPA0355 promotes osteoblast differentiation, increases alkaline phosphatase activity, and enhances mineral nodule formation. SPA0355 can protect ovariectomized mice from bone loss by stimulating osteoblast differentiation and inhibiting osteoclast resorption, making it useful for studying postmenopausal osteoporosis.
    SPA0355
  • HY-169731
    RO27-3225 trifluoroacetate 1373926-49-8
    RO27-3225 trifluoroacetate is a peptide agonist of melanocortin receptor 4 (MC4R) with neuroprotective and anti-inflammatory activity with an EC50 value of 1 nM, while 8 nM for MC1R. RO27-3225 trifluoroacetate reverses hemorrhagic shock, reduces brain edema, blood-brain barrier (BBB) permeability, and hippocampal IL-1β and TNF-α levels in a rat model of intra-abdominal hypertension induced by hemorrhagic shock and resuscitation.
    RO27-3225 trifluoroacetate
Cat. No. Product Name / Synonyms Application Reactivity